Tirzepatide (Mounjaro®) Pen

Tirzepatide (Mounjaro®)

Overview
Tirzepatide is a breakthrough dual-action medication designed for adults with type 2 diabetes or obesity. It is available as a pre-filled injection pen (KwikPen®) for subcutaneous use, typically administered once per week. Approved in 2022, it represents a new class of therapy that combines GLP-1 receptor agonist and GIP receptor agonist activity, offering enhanced control of blood sugar and body weight.

Key Features & Benefits

• Dual hormone action: Activates both GLP-1 and GIP receptors to improve insulin secretion and reduce appetite.
• Blood sugar control: Helps lower HbA1c levels in adults with type 2 diabetes.
• Weight management: Clinically proven to support significant weight loss when combined with diet and physical activity.
• Convenient dosing: Once-weekly injection via easy-to-use prefilled pens (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg options).
• Versatile use: Can be prescribed alone (for patients intolerant to metformin) or alongside other diabetes medications.

Indications

• Adults with type 2 diabetes not adequately controlled by diet and exercise.
• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related health conditions such as hypertension, sleep apnea, or dyslipidemia.

Safety Information

• Boxed Warning: Tirzepatide has been shown to cause thyroid C-cell tumors in rats. The relevance to humans is unknown, but it is contraindicated in patients with a personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Common side effects: Nausea, diarrhea, decreased appetite, vomiting, and constipation.
• Precautions: Patients should be counseled on symptoms of thyroid tumors and monitored for gastrointestinal side effects.

Formulation & Packaging

• Supplied in single-dose vials or pre-filled KwikPen® autoinjectors.
• Strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL.

 

Market & Resale Potential

• High demand: Tirzepatide is part of the booming GLP-1 medication market, alongside semaglutide (Ozempic/Wegovy).
• Resale appeal: Strong interest from wellness and weight-loss communities, making it a high-value pharmaceutical product.